C-myc, not HER-2/neu, correlates with early recurrence of node-negative breast cancers.

被引：0
|
作者：
Schlotter, CM [1 ]
Vogt, U [1 ]
Bosse, U [1 ]
Wassmann, K [1 ]
机构：
[1] Dept Obstet & Gynecol, Ibbenbueren, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页码：262 / 262
页数：1
相关论文
共 50 条
  • [21] Clinical relevance of HER-2 expression in node-negative breast cancer patients.
    Sun, JM
    Han, W
    Kim, DW
    Kim, TY
    Park, IAE
    Noh, DY
    Heo, DS
    Bang, YJ
    Choe, KJ
    Kim, NK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 26S - 26S
  • [22] HER-2/NEU ONCOGENE EXPRESSION AND PROLIFERATION IN BREAST CANCERS
    BACUS, SS
    RUBY, SG
    WEINBERG, DS
    CHIN, D
    ORTIZ, R
    BACUS, JW
    AMERICAN JOURNAL OF PATHOLOGY, 1990, 137 (01): : 103 - 111
  • [23] The association of HER-2/neu amplification with breast cancer recurrence
    Carr, JA
    Havstad, S
    Zarbo, RJ
    Divine, G
    Mackowiak, P
    Velanovich, V
    ARCHIVES OF SURGERY, 2000, 135 (12) : 1469 - 1474
  • [24] Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers
    Janocko, LE
    Brown, KA
    Smith, CA
    Gu, LP
    Pollice, AA
    Singh, SG
    Julian, T
    Wolmark, N
    Sweeney, L
    Silverman, JF
    Shackney, SE
    CYTOMETRY, 2001, 46 (03): : 136 - 149
  • [25] HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
    Harbeck, N
    Ross, JS
    Yurdseven, S
    Dettmar, P
    Pölcher, M
    Kuhn, W
    Ulm, K
    Graeff, H
    Schmitt, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 14 (04) : 663 - 671
  • [26] Structural alterations of C-MYC, HER-2/neu and CCND1 oncogenes in hyperparathyroidism.
    Gogusev, J
    Doussau, M
    Jaubert, F
    Sarfati, E
    Telvi, L
    Drueke, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 587A - 587A
  • [27] Recurrence risk in small, node-negative, early breast cancer
    Nagaoka, R.
    Horiguchi, J.
    Takata, D.
    Sato, A.
    Tokiniwa, H.
    Higuchi, T.
    Uchida, S.
    Tsuboi, M.
    Kikuchi, M.
    Takeyoshi, I.
    BREAST, 2015, 24 : S118 - S119
  • [28] CORRELATION OF C-MYC AND HER-2/NEU AMPLIFICATION AND EXPRESSION WITH HISTOPATHOLOGIC VARIABLES IN UTERINE CORPUS CANCER
    MONK, BJ
    CHAPMAN, JA
    JOHNSON, GA
    BRIGHTMAN, BK
    WILCZYNSKI, SP
    SCHELL, MJ
    FAN, H
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 171 (05) : 1193 - 1198
  • [29] Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma
    Chung, TKH
    Cheung, TH
    To, KF
    Wong, YF
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2000, 49 (01) : 47 - 51
  • [30] AMPLIFICATION OF C-MYC AND C-ERB-BETA-2 (HER-2/NEU) IN BREAST-CANCER WITHOUT LYMPH-NODE INVOLVEMENT - CORRELATION WITH OTHER PROGNOSTIC PARAMETERS
    LIZARDNACOL, S
    ARNOULD, L
    RIEDINGER, JM
    ARNAL, M
    COLLIN, F
    GUERRIN, J
    BULLETIN DU CANCER, 1994, 81 (09) : 780 - 784
12345